Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine
- PMID: 4008629
- PMCID: PMC271838
- DOI: 10.1128/jcm.21.6.997-999.1985
Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine
Abstract
The infectivity and immunogenicity of live attenuated A/Washington/897/80 cold-adapted reassortant virus vaccine was evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:4) and seropositive (hemagglutination inhibition titer, greater than 1:4) adult volunteers. The vaccine was efficient in infecting seronegative volunteers (94%). Moreover, 51% of seropositive vaccinees were infected by the virus. After live virus vaccination, greater than 83% of both seronegative and seropositive vaccinees achieved a level of nasal wash antibody previously associated with resistance to infection with influenza A virus. These findings indicate that both seronegative and seropositive vaccinees can benefit from live virus vaccination.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
